Mediators of inflammation and bone remodeling in rheumatic disease

Seminars in Cell and Developmental Biology

Volumn 49, Issue , 2016, Pages 2-10

  Shaw, Anita T ^a   Gravallese, Ellen M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Cytokines; Inflammation; Osteoblasts; Osteoclasts; Rheumatoid arthritis; Spondyloarthritis

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CYTOKINE; MICRORNA; AUTACOID;

ANKYLOSING SPONDYLITIS; BONE EROSION; BONE REMODELING; CELL DIFFERENTIATION; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; MECHANICAL STRESS; MOLECULAR PATHOLOGY; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OUTCOME ASSESSMENT; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; SPONDYLOARTHROPATHY; WNT SIGNALING PATHWAY; ANIMAL; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE RESORPTION; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; OSTEOBLASTS; OSTEOCLASTS; SIGNAL TRANSDUCTION;

EID: 84958599224     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2015.10.013     Document Type: Review

References (119)

1. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3597-3602.
2. Pettit A.R., Ji H., von Stechow D., Muller R., Goldring S.R., Choi Y., et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 2001, 159:1689-1699.
3. Koga T., Inui M., Inoue K., Kim S., Suematsu A., Kobayashi E., et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004, 428:758-763.
4. Humphrey M.B., Lanier L.L., Nakamura M.C. Role of ITAM-containing adapter proteins and their receptors in the immune system and bone. Immunol. Rev. 2005, 208:50-65.
5. Cella M., Buonsanti C., Strader C., Kondo T., Salmaggi A., Colonna M. Impaired differentiation of osteoclasts in TREM-2-deficient individuals. J. Exp. Med. 2003, 198:645-651.
6. Kaifu T., Nakahara J., Inui M., Mishima K., Momiyama T., Kaji M., et al. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J. Clin. Invest. 2003, 111:323-332.
7. Crotti T.N., Dharmapatni A.A., Alias E., Zannettino A.C., Smith M.D., Haynes D.R. The immunoreceptor tyrosine-based activation motif (ITAM)-related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints. Arthritis Res. Ther. 2012, 14:R245.
8. Braun T., Zwerina J. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res. Ther. 2011, 13:235.
9. Chen Z., Buki K., Vaaraniemi J., Gu G., Vaananen H.K. The critical role of IL-34 in osteoclastogenesis. PLoS ONE 2011, 6:e18689.
10. Shioi A., Teitelbaum S.L., Ross F.P., Welgus H.G., Suzuki H., Ohara J., et al. Interleukin 4 inhibits murine osteoclast formation in vitro. J. Cell. Biochem. 1991, 47:272-277.
11. Takayanagi H., Kim S., Matsuo K., Suzuki H., Suzuki T., Sato K., et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002, 416:744-749.
12. Yamada N., Niwa S., Tsujimura T., Iwasaki T., Sugihara A., Futani H., et al. Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity. Bone 2002, 30:901-908.
13. Yoshimatsu M., Kitaura H., Fujimura Y., Eguchi T., Kohara H., Morita Y., et al. IL-12 inhibits TNF-alpha induced osteoclastogenesis via a T cell-independent mechanism in vivo. Bone 2009, 45:1010-1016.
14. Kiyomiya H., Ariyoshi W., Okinaga T., Kaneuji T., Mitsugi S., Sakurai T., et al. IL-33 inhibits RANKL-induced osteoclast formation through the regulation of Blimp-1 and IRF-8 expression. Biochem. Biophys. Res. Commun. 2015, 460:320-326.
15. Schulze J., Bickert T., Beil F.T., Zaiss M.M., Albers J., Wintges K., et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J. Bone Miner. Res. 2011, 26:704-717.
16. Zaiss M.M., Kurowska-Stolarska M., Bohm C., Gary R., Scholtysek C., Stolarski B., et al. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. J. Immunol. 2011, 186:6097-6105.
17. Keller J., Catala-Lehnen P., Wintges K., Schulze J., Bickert T., Ito W., et al. Transgenic over-expression of interleukin-33 in osteoblasts results in decreased osteoclastogenesis. Biochem. Biophys. Res. Commun. 2012, 417:217-222.
18. Schwarz E.M., Looney R.J., Drissi M.H., O'Keefe R.J., Boyce B.F., Xing L., et al. Autoimmunity and bone. Ann. N. Y. Acad. Sci. 2006, 1068:275-283.
19. Horwood N.J., Udagawa N., Elliott J., Grail D., Okamura H., Kurimoto M., et al. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J. Clin. Invest. 1998, 101:595-603.
20. Rosen V. BMP and BMP inhibitors in bone. Ann. N. Y. Acad. Sci. 2006, 1068:19-25.
21. Matsubara T., Kida K., Yamaguchi A., Hata K., Ichida F., Meguro H., et al. BMP2 regulates Osterix through Msx2 and Runx2 during osteoblast differentiation. J. Biol. Chem. 2008, 283:29119-29125.
22. Daluiski A., Engstrand T., Bahamonde M.E., Gamer L.W., Agius E., Stevenson S.L., et al. Bone morphogenetic protein-3 is a negative regulator of bone density. Nat. Genet. 2001, 27:84-88.
23. Rawadi G., Vayssiere B., Dunn F., Baron R., Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J. Bone Miner. Res. 2003, 18:1842-1853.
24. Heiland G.R., Zwerina K., Baum W., Kireva T., Distler J.H., Grisanti M., et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann. Rheum. Dis. 2010, 69:2152-2159.
25. Bodine P.V., Zhao W., Kharode Y.P., Bex F.J., Lambert A.J., Goad M.B., et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol. Endocrinol. 2004, 18:1222-1237.
26. Morvan F., Boulukos K., Clement-Lacroix P., Roman Roman S., Suc-Royer I., Vayssiere B., et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J. Bone Miner. Res. 2006, 21:934-945.
27. Li J., Sarosi I., Cattley R.C., Pretorius J., Asuncion F., Grisanti M., et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 2006, 39:754-766.
28. Yao W., Cheng Z., Shahnazari M., Dai W., Johnson M.L., Lane N.E. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J. Bone Miner. Res. 2010, 25:190-199.
29. Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 2001, 10:537-543.
30. Balemans W., Patel N., Ebeling M., Van Hul E., Wuyts W., Lacza C., et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 2002, 39:91-97.
31. Lian J.B., Stein G.S., van Wijnen A.J., Stein J.L., Hassan M.Q., Gaur T., et al. MicroRNA control of bone formation and homeostasis. Nat. Rev. Endocrinol. 2012, 8:212-227.
32. Kapinas K., Kessler C., Ricks T., Gronowicz G., Delany A.M. miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J. Biol. Chem. 2010, 285:25221-25231.
33. Li Z., Hassan M.Q., Jafferji M., Aqeilan R.I., Garzon R., Croce C.M., et al. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J. Biol. Chem. 2009, 284:15676-15684.
34. Zhang J., Tu Q., Bonewald L.F., He X., Stein G., Lian J., et al. Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1. J. Bone Miner. Res. 2011, 26:1953-1963.
35. Zhang Y., Xie R.L., Croce C.M., Stein J.L., Lian J.B., van Wijnen A.J., et al. A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9863-9868.
36. Li Z., Hassan M.Q., Volinia S., van Wijnen A.J., Stein J.L., Croce C.M., et al. A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13906-13911.
37. Jia J., Tian Q., Ling S., Liu Y., Yang S., Shao Z. miR-145 suppresses osteogenic differentiation by targeting Sp7. FEBS Lett. 2013, 587:3027-3031.
38. Crotti T.N., Smith M.D., Weedon H., Ahern M.J., Findlay D.M., Kraan M., et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann. Rheum. Dis. 2002, 61:1047-1054.
39. Gravallese E.M., Manning C., Tsay A., Naito A., Pan C., Amento E., et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000, 43:250-258.
40. Wong P.K., Quinn J.M., Sims N.A., van Nieuwenhuijze A., Campbell I.K., Wicks I.P. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 2006, 54:158-168.
41. Zhang Y.H., Heulsmann A., Tondravi M.M., Mukherjee A., Abu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J. Biol. Chem. 2001, 276:563-568.
42. Yao Z., Li P., Zhang Q., Schwarz E.M., Keng P., Arbini A., et al. Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J. Biol. Chem. 2006, 281:11846-11855.
43. Yarilina A., Xu K., Chen J., Ivashkiv L.B. TNF activates calcium-nuclear factor of activated T cells (NFAT)c1 signaling pathways in human macrophages. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1573-1578.
44. Herman S., Muller R.B., Kronke G., Zwerina J., Redlich K., Hueber A.J., et al. Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum. 2008, 58:3041-3050.
45. Huang H., Zhao N., Xu X., Xu Y., Li S., Zhang J., et al. Dose-specific effects of tumor necrosis factor alpha on osteogenic differentiation of mesenchymal stem cells. Cell Prolif. 2011, 44:420-427.
46. Gilbert L., He X., Farmer P., Rubin J., Drissi H., van Wijnen A.J., et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J. Biol. Chem. 2002, 277:2695-2701.
47. Gilbert L., He X., Farmer P., Boden S., Kozlowski M., Rubin J., et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000, 141:3956-3964.
48. Jilka R.L., Weinstein R.S., Bellido T., Parfitt A.M., Manolagas S.C. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J. Bone Miner. Res. 1998, 13:793-802.
49. Stashenko P., Dewhirst F.E., Rooney M.L., Desjardins L.A., Heeley J.D. Interleukin-1 beta is a potent inhibitor of bone formation in vitro. J. Bone Miner. Res. 1987, 2:559-565.
50. Tang Y., Wu X., Lei W., Pang L., Wan C., Shi Z., et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 2009, 15:757-765.
51. Centrella M., McCarthy T.L., Canalis E. Skeletal tissue and transforming growth factor beta. FASEB J. 1988, 2:3066-3073.
52. Wei S., Kitaura H., Zhou P., Ross F.P., Teitelbaum S.L. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 2005, 115:282-290.
53. Manolagas S.C. Role of cytokines in bone resorption. Bone 1995, 17:63S-67S.
54. Yoshitake F., Itoh S., Narita H., Ishihara K., Ebisu S. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J. Biol. Chem. 2008, 283:11535-11540.
55. Axmann R., Bohm C., Kronke G., Zwerina J., Smolen J., Schett G. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum. 2009, 60:2747-2756.
56. Takagi N., Mihara M., Moriya Y., Nishimoto N., Yoshizaki K., Kishimoto T., et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 1998, 41:2117-2121.
57. Smolen J.S., Avila J.C., Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann. Rheum. Dis. 2012, 71:687-693.
58. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
59. Zhang F., Tanaka H., Kawato T., Kitami S., Nakai K., Motohashi M., et al. Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts. Biochimie 2011, 93:296-305.
60. Bush K.A., Farmer K.M., Walker J.S., Kirkham B.W. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 2002, 46:802-805.
61. Koenders M.I., Lubberts E., Oppers-Walgreen B., van den Bersselaar L., Helsen M.M., Di Padova F.E., et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am. J. Pathol. 2005, 167:141-149.
62. Lubberts E., Koenders M.I., Oppers-Walgreen B., van den Bersselaar L., Coenen-de Roo C.J., Joosten L.A., et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 2004, 50:650-659.
63. Adamopoulos I.E., Suzuki E., Chao C.C., Gorman D., Adda S., Maverakis E., et al. IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis. Ann. Rheum. Dis. 2015, 74:1284-1292.
64. Genovese M.C., Durez P., Richards H.B., Supronik J., Dokoupilova E., Mazurov V., et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann. Rheum. Dis. 2013, 72:863-869.
65. Genovese M.C., Greenwald M., Cho C.S., Berman A., Jin L., Cameron G.S., et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheum. 2014, 66:1693-1704.
66. Pavelka K., Chon Y., Newmark R., Lin S.L., Baumgartner S., Erondu N. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J. Rheumatol. 2015, 42:912-919.
67. Fischer J.A., Hueber A.J., Wilson S., Galm M., Baum W., Kitson C., et al. Combined inhibition of tumor necrosis factor alpha and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheum. 2015, 67:51-62.
68. Zhang F., Ding R., Li P., Ma C., Song D., Wang X., et al. Interleukin-34 in rheumatoid arthritis: potential role in clinical therapy. Int. J. Clin. Exp. Med. 2015, 8:7809-7815.
69. Hwang S.J., Choi B., Kang S.S., Chang J.H., Kim Y.G., Chung Y.H., et al. Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis. Arthritis Res. Ther. 2012, 14:R14.
70. Chemel M., Le Goff B., Brion R., Cozic C., Berreur M., Amiaud J., et al. Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. Ann. Rheum. Dis. 2012, 71:150-154.
71. Katsikis P.D., Chu C.Q., Brennan F.M., Maini R.N., Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J. Exp. Med. 1994, 179:1517-1527.
72. van Roon J.A., Lafeber F.P., Bijlsma J.W. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum. 2001, 44:3-12.
73. Ideguchi H., Ohno S., Hattori H., Senuma A., Ishigatsubo Y. Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs. Arthritis Res. Ther. 2006, 8:R76.
74. Finzel S., Rech J., Schmidt S., Engelke K., Englbrecht M., Schett G. Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study. Ann. Rheum. Dis. 2013, 72:396-400.
75. Finzel S., Rech J., Schmidt S., Engelke K., Englbrecht M., Stach C., et al. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion. Ann. Rheum. Dis. 2011, 70:1587-1593.
76. Walsh N.C., Reinwald S., Manning C.A., Condon K.W., Iwata K., Burr D.B., et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J. Bone Miner. Res. 2009, 24:1572-1585.
77. Matzelle M.M., Gallant M.A., Condon K.W., Walsh N.C., Manning C.A., Stein G.S., et al. Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis Rheum. 2012, 64:1540-1550.
78. Diarra D., Stolina M., Polzer K., Zwerina J., Ominsky M.S., Dwyer D., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 2007, 13:156-163.
79. Uderhardt S., Diarra D., Katzenbeisser J., David J.P., Zwerina J., Richards W., et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann. Rheum. Dis. 2010, 69:592-597.
80. Yeremenko N., Zwerina K., Rigter G., Pots D., Fonseca J.E., Zwerina J., et al. Brief report: tumor necrosis factor and interleukin-6 differentially regulate Dkk-1 in the inflamed arthritic joint. Arthritis Rheum. 2015, 67:2071-2075.
81. Colonna M. TREMs in the immune system and beyond. Nat. Rev. Immunol. 2003, 3:445-453.
82. Chen X., Eksioglu E.A., Carter J.D., Fortenbery N., Donatelli S.S., Zhou J., et al. Inactivation of DAP12 in PMN inhibits TREM1-mediated activation in rheumatoid arthritis. PLOS ONE 2015, 10:e0115116.
83. Shimizu T., Takahata M., Kameda Y., Endo T., Hamano H., Hiratsuka S., et al. Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) mediates periarticular bone loss, but not joint destruction, in murine antigen-induced arthritis. Bone 2015, 79:65-70.
84. Bar-Shavit Z. Taking a toll on the bones: regulation of bone metabolism by innate immune regulators. Autoimmunity 2008, 41:195-203.
85. Itoh K., Udagawa N., Kobayashi K., Suda K., Li X., Takami M., et al. Lipopolysaccharide promotes the survival of osteoclasts via toll-like receptor 4, but cytokine production of osteoclasts in response to lipopolysaccharide is different from that of macrophages. J. Immunol. 2003, 170:3688-3695.
86. Kassem A., Henning P., Kindlund B., Lindholm C., Lerner U.H. TLR5, a novel mediator of innate immunity-induced osteoclastogenesis and bone loss. FASEB J. 2015, pii: fj.15-272559.
87. Chamberlain N.D., Vila O.M., Volin M.V., Volkov S., Pope R.M., Swedler W., et al. TLR5, a novel and unidentified inflammatory mediator in rheumatoid arthritis that correlates with disease activity score and joint TNF-alpha levels. J. Immunol. 2012, 189:475-483.
88. Kurowska-Stolarska M., Alivernini S., Ballantine L.E., Asquith D.L., Millar N.L., Gilchrist D.S., et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:11193-11198.
89. Stanczyk J., Pedrioli D.M., Brentano F., Sanchez-Pernaute O., Kolling C., Gay R.E., et al. Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008, 58:1001-1009.
90. Bluml S., Bonelli M., Niederreiter B., Puchner A., Mayr G., Hayer S., et al. Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum. 2011, 63:1281-1288.
91. Fulci V., Scappucci G., Sebastiani G.D., Giannitti C., Franceschini D., Meloni F., et al. miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum. Immunol. 2010, 71:206-211.
92. Sugatani T., Hruska K.A. Impaired micro-RNA pathways diminish osteoclast differentiation and function. J. Biol. Chem. 2009, 284:4667-4678.
93. Li Y.T., Chen S.Y., Wang C.R., Liu M.F., Lin C.C., Jou I.M., et al. Brief report: amelioration of collagen-induced arthritis in mice by lentivirus-mediated silencing of microRNA-223. Arthritis Rheum. 2012, 64:3240-3245.
94. Nakasa T., Shibuya H., Nagata Y., Niimoto T., Ochi M. The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum. 2011, 63:1582-1590.
95. McGeachy M.J., Chen Y., Tato C.M., Laurence A., Joyce-Shaikh B., Blumenschein W.M., et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat. Immunol. 2009, 10:314-324.
96. Mei Y., Pan F., Gao J., Ge R., Duan Z., Zeng Z., et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin. Rheumatol. 2011, 30:269-273.
97. Duan Z., Pan F., Zeng Z., Zhang T., Wang S., Li G., et al. Interleukin-23 receptor genetic polymorphisms and ankylosing spondylitis susceptibility: a meta-analysis. Rheumatol. Int. 2012, 32:1209-1214.
98. Appel H., Maier R., Bleil J., Hempfing A., Loddenkemper C., Schlichting U., et al. In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum. 2013, 65:1522-1529.
99. Appel H., Maier R., Wu P., Scheer R., Hempfing A., Kayser R., et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res. Ther. 2011, 13:R95.
100. Jandus C., Bioley G., Rivals J.P., Dudler J., Speiser D., Romero P. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008, 58:2307-2317.
101. Menon B., Gullick N.J., Walter G.J., Rajasekhar M., Garrood T., Evans H.G., et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheum. 2014, 66:1272-1281.
102. Chen W.S., Chang Y.S., Lin K.C., Lai C.C., Wang S.H., Hsiao K.H., et al. Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. J. Chin. Med. Assoc. 2012, 75:303-308.
103. Andersen T., Rasmussen T.K., Hvid M., Holm C.K., Madsen K.J., Jurik A.G., et al. Increased plasma levels of IL-21 and IL-23 in spondyloarthritis are not associated with clinical and MRI findings. Rheumatol. Int. 2012, 32:387-393.
104. Francois R.J., Neure L., Sieper J., Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann. Rheum. Dis. 2006, 65:713-720.
105. Braun J., Bollow M., Neure L., Seipelt E., Seyrekbasan F., Herbst H., et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995, 38:499-505.
106. Sveaas S.H., Berg I.J., Provan S.A., Semb A.G., Olsen I.C., Ueland T., et al. Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study. Scand. J. Rheumatol. 2015, 44:118-124.
107. Sherlock J.P., Joyce-Shaikh B., Turner S.P., Chao C.C., Sathe M., Grein J., et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat. Med. 2012, 18:1069-1076.
108. Kang Y.K., Zhang M.C. IL-23 promotes osteoclastogenesis in osteoblast-osteoclast co-culture system. Genet. Mol. Res. 2014, 13:4673-4679.
109. Jacques P., Lambrecht S., Verheugen E., Pauwels E., Kollias G., Armaka M., et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann. Rheum. Dis. 2014, 73:437-445.
110. Lories R.J., Derese I., Luyten F.P. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J. Clin. Invest. 2005, 115:1571-1579.
111. Lories R.J., Schett G. Pathophysiology of new bone formation and ankylosis in spondyloarthritis. Rheum. Dis. Clin. North Am. 2012, 38:555-567.
112. Chen H.A., Chen C.H., Lin Y.J., Chen P.C., Chen W.S., Lu C.L., et al. Association of bone morphogenetic proteins with spinal fusion in ankylosing spondylitis. J. Rheumatol. 2010, 37:2126-2132.
113. Lories R.J., Derese I., Ceuppens J.L., Luyten F.P. Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum. 2003, 48:2807-2818.
114. Daoussis D., Liossis S.N., Solomou E.E., Tsanaktsi A., Bounia K., Karampetsou M., et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum. 2010, 62:150-158.
115. Heiland G.R., Appel H., Poddubnyy D., Zwerina J., Hueber A., Haibel H., et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann. Rheum. Dis. 2012, 71:572-574.
116. Kwon S.R., Lim M.J., Suh C.H., Park S.G., Hong Y.S., Yoon B.Y., et al. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol. Int. 2012, 32:2523-2527.
117. Yucong Z., Lu L., Shengfa L., Yongliang Y., Ruguo S., Yikai L. Serum functional dickkopf-1 levels are inversely correlated with radiographic severity of ankylosing spondylitis. Clin. Lab. 2014, 60:1527-1531.
118. Appel H., Ruiz-Heiland G., Listing J., Zwerina J., Herrmann M., Mueller R., et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009, 60:3257-3262.
119. Haynes K.R., Pettit A.R., Duan R., Tseng H.W., Glant T.T., Brown M.A., et al. Excessive bone formation in a mouse model of ankylosing spondylitis is associated with decreases in Wnt pathway inhibitors. Arthritis Res. Ther. 2012, 14:R253.